Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology

26-04-2024 | Magnetic Resonance Imaging | Head and Neck

Impact of magnetic resonance imaging-derived skeletal muscle index in locoregionally advanced nasopharyngeal carcinoma

Authors: Jiali Jiang, Zhuochen Cai, Ronghui Zheng, Yawei Yuan, Xing Lv, Wenze Qiu

Published in: European Archives of Oto-Rhino-Laryngology

Login to get access

Abstract

Purpose

To evaluate the clinical implication of magnetic resonance imaging (MRI)-derived skeletal muscle index (SMI) in locoregionally advanced nasopharyngeal carcinoma (LANPC) patients undergoing induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) and further to develop a nomogram for predicting survival prognosis.

Methods

SMI was determined through baseline MRI at the third cervical level. The nomogram was based on a training cohort involving 409 LANPC patients. We validated the prognostic accuracy of this prognostic model in an internal validation cohort (n = 204) and an external independent cohort (n = 272).

Results

SMI was an independent risk factor for OS. A prognostic model comprising age, TNM stage and SMI for individual survival prediction was developed and graphically represented as a nomogram. The model showed favorable discrimination (C-index: 0.686), predictive accuracy [time dependent area under the curve (tAUC) at 5 years: 0.70], and calibration, and was further validated in the internal and external validation datasets. A risk stratification derived from the model stratified these patients into three prognostic subgroups with significantly different survival.

Conclusions

Low SMI accessed by MRI was significantly associated with poor overall survival in LANPC patients undergoing IC + CCRT. Moreover, we established and validated a novel nomogram involving age, TNM stage and SMI that could provide accurate prognostic stratification among this population.
Appendix
Available only for authorised users
Literature
1.
2.
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249CrossRefPubMed
3.
Zhang Y, Chen L, Hu GQ et al (2019) Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 381:1124–1135CrossRefPubMed
4.
Tang XR, Li YQ, Liang SB et al (2018) Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol 19:382–393CrossRefPubMed
5.
Hui EP, Li WF, Ma BB et al (2020) Integrating postradiotherapy plasma Epstein–Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Ann Oncol 31:769–779CrossRefPubMed
6.
Cespedes Feliciano E, Chen WY (2018) Clinical implications of low skeletal muscle mass in early-stage breast and colorectal cancer. Proc Nutr Soc 77:382–387CrossRefPubMed
7.
Uojima H, Chuma M, Tanaka Y et al (2020) Skeletal muscle mass influences tolerability and prognosis in hepatocellular carcinoma patients treated with lenvatinib. Liver cancer 9:193–206CrossRefPubMed
8.
Jin Y, Ma X, Yang Z et al (2023) Low L3 skeletal muscle index associated with the clinicopathological characteristics and prognosis of ovarian cancer: a meta-analysis. J Cachexia Sarcopenia Muscle 14:697–705CrossRefPubMedPubMedCentral
9.
Chang SW, Hsu CM, Tsai YH et al (2021) Prognostic value of third cervical vertebra skeletal muscle index in oral cavity cancer: a retrospective study. Laryngoscope 131:E2257–E2265CrossRefPubMed
10.
Hua X, Liao JF, Huang X et al (2020) Sarcopenia is associated with higher toxicity and poor prognosis of nasopharyngeal carcinoma. Ther Adv Med Oncol 12:1758835920947612CrossRefPubMedPubMedCentral
11.
Liu S, Zou Y, Zhong M et al (2023) Prognostic significance of MRI-defined sarcopenia in patients with nasopharyngeal carcinoma: a propensity score matched analysis of real-world data. Radiother Oncol 188:109904CrossRefPubMed
12.
Nagpal P, Pruthi DS, Pandey M et al (2021) Impact of sarcopenia in locally advanced head and neck cancer treated with chemoradiation: an Indian tertiary care hospital experience. Oral Oncol 121:105483CrossRefPubMed
13.
van Rijn-Dekker MI, van den Bosch L, van den Hoek JGM et al (2020) Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy. Radiother Oncol 147:103–110CrossRefPubMed
14.
Zwart AT, Becker JN, Lamers MJ et al (2021) Skeletal muscle mass and sarcopenia can be determined with 1.5-T and 3-T neck MRI scans, in the event that no neck CT scan is performed. Eur Radiol 31:4053–4062CrossRefPubMed
15.
Swartz JE, Pothen AJ, Wegner I et al (2016) Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncol 62:28–33CrossRefPubMed
16.
Qiang M, Li C, Sun Y et al (2021) A prognostic predictive system based on deep learning for locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 113:606–615CrossRefPubMed
17.
Zhuang CL, Huang DD, Pang WY et al (2016) Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a large-scale cohort. Medicine (Baltimore) 95:e3164CrossRefPubMed
18.
Huang X, Ma J, Li L et al (2019) Severe muscle loss during radical chemoradiotherapy for non-metastatic nasopharyngeal carcinoma predicts poor survival. Cancer Med 8:6604–6613CrossRefPubMedPubMedCentral
19.
Huang X, Lv LN, Zhao Y et al (2021) Is skeletal muscle loss associated with chemoradiotherapy toxicity in nasopharyngeal carcinoma patients? A prospective study. Clin Nutr 40:295–302CrossRefPubMed
20.
He WZ, Jiang C, Liu LL et al (2020) Association of body composition with survival and inflammatory responses in patients with non-metastatic nasopharyngeal cancer. Oral Oncol 108:104771CrossRefPubMed
21.
Xing X, Zhou X, Yang Y et al (2021) The impact of body composition parameters on severe toxicities in patients with locoregionally advanced nasopharyngeal carcinoma undergoing neoadjuvant chemotherapy. Ann Transl Med 9:1180CrossRefPubMedPubMedCentral
22.
Hua X, Li WZ, Huang X et al (2021) Modeling sarcopenia to predict survival for patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy. front Oncol 11:625534CrossRefPubMedPubMedCentral
23.
Huang HY, Lin F, Chen XY et al (2021) A model combining skeletal muscle mass and a hematological biomarker to predict survival in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy. Front Oncol 11:644676CrossRefPubMedPubMedCentral
24.
Baracos VE (2000) Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. Nutrition 16:1015–1018CrossRefPubMed
25.
Fearon KC, Glass DJ, Guttridge DC (2012) Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 16:153–166CrossRefPubMed
26.
Rong YD, Bian AL, Hu HY et al (2018) Study on relationship between elderly sarcopenia and inflammatory cytokine IL-6, anti-inflammatory cytokine IL-10. BMC Geriatr 18:308CrossRefPubMedPubMedCentral
27.
Karstoft K, Pedersen BK (2016) Skeletal muscle as a gene regulatory endocrine organ. Curr Opin Clin Nutr Metab Care 19:270–275CrossRefPubMed
28.
Huang XD, Zhou GQ, Lv JW et al (2018) Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data, intelligence platform-based analysis. Radiother Oncol 129:389–395CrossRefPubMed
29.
Wu SG, Liao XL, He ZY et al (2017) Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: a population-based analysis. Oral Oncol 73:83–87CrossRefPubMed
30.
Chen YP, Liu X, Zhou Q et al (2021) Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 398:303–313CrossRefPubMed
31.
Meng L, Wei J, Ji R et al (2019) Effect of early nutrition intervention on advanced nasopharyngeal carcinoma patients receiving chemoradiotherapy. J Cancer 10:3650–3656CrossRefPubMedPubMedCentral
32.
Xiao W, Chan CW, Jinnan X et al (2021) Managing the nutrition impact symptom cluster in patients with nasopharyngeal carcinoma using an educational intervention program: a pilot study. Eur J Oncol Nurs 53:101980CrossRefPubMed
33.
Miao J, Wang L, Ong EHW et al (2023) Effects of induction chemotherapy on nutrition status in locally advanced nasopharyngeal carcinoma: a multicentre prospective study. J Cachexia Sarcopenia Muscle 14:815–825CrossRefPubMedPubMedCentral
Metadata
Title
Impact of magnetic resonance imaging-derived skeletal muscle index in locoregionally advanced nasopharyngeal carcinoma
Authors
Jiali Jiang
Zhuochen Cai
Ronghui Zheng
Yawei Yuan
Xing Lv
Wenze Qiu
Publication date
26-04-2024
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Oto-Rhino-Laryngology
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-024-08572-6